Galapagos NV (GLPG): Price and Financial Metrics
GET POWR RATINGS... FREE!
GLPG Stock Price Chart Interactive Chart >
GLPG Price/Volume Stats
|Current price||$44.19||52-week high||$72.11|
|Prev. close||$44.57||52-week low||$37.24|
|Day high||$44.55||Avg. volume||110,595|
|50-day MA||$42.38||Dividend yield||N/A|
|200-day MA||$49.73||Market Cap||2.91B|
Galapagos NV (GLPG) Company Bio
Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines in areas such as cystic fibrosis, inflammation, and other indications. The company was founded in 1999 and is Mechelen, Belgium.
Most Popular Stories View All
GLPG Latest News Stream
|Loading, please wait...|
GLPG Latest Social Stream
View Full GLPG Social Stream
Latest GLPG News From Around the Web
Below are the latest news stories about GALAPAGOS NV that investors may wish to consider to help them evaluate GLPG as an investment opportunity.
Mechelen, Belgium; 10 January 2023, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 9 January 2023 from FMR LLC, who notified that it holds 3,903,804 of Galapagos’ voting rights, consisting of 3,801,504 ordinary shares and 102,300 equivalent financial instruments. FMR LLC controls investment funds Fidelity Management & Resea
Mechelen, Belgium; 3 January 2023, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 41th Annual J.P. Morgan Healthcare Conference on January 9-12, 2023. Paul Stoffels1, CEO, will present on Monday, January 9 at 4.30 p.m. PST/7.30 p.m. ET (Tuesday, January 10 at 01.30 a.m. CET). The presentation will be a live audio webcast and can be accessed via the following link. A replay of the webcast will be available on the Galapagos’ website at https://www.glpg.com/webcasts. Abou
Galapagos is setting up to transform its business after a slew of failures. Read more to see why I think GLPG will be successful in its transformation plans.
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Mechelen, Belgium; 22 December 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced changes in the Executive Committee effective 1 January 2023. Dr. Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022. He will stay with Galapagos until 31 May 2023 to ensure a smooth transition. The company also announces the retirement of André Hoekema who joined Galapagos in 2005 as Chief Business Off
GLPG Price Returns